Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim

[1]  J. Horng,et al.  Incidence of immune thrombocytopenia in Taiwan: a nationwide population‐based study , 2018, Transfusion.

[2]  Yu-Hsiang Chang,et al.  Incidence, clinical characteristics, and associated diseases in patients with immune thrombocytopenia: A nationwide population-based study in Taiwan. , 2018, Thrombosis research.

[3]  Ji‐Won Kim,et al.  Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. , 2017, Thrombosis research.

[4]  M. Lambert,et al.  Clinical updates in adult immune thrombocytopenia. , 2017, Blood.

[5]  K. Michaëlsson,et al.  Registers of the Swedish total population and their use in medical research , 2016, European Journal of Epidemiology.

[6]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[7]  M. Calaminici,et al.  United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings , 2015, British journal of haematology.

[8]  M. Lapeyre-Mestre,et al.  Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. , 2014, Blood.

[9]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[10]  J. Bussel,et al.  Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up , 2014, Haematologica.

[11]  C. Stoltenberg,et al.  [The Norwegian patient register--an important source for research]. , 2014, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[12]  J. Bussel,et al.  Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities , 2012, Modern Pathology.

[13]  Xingmin Feng,et al.  Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents , 2011, British journal of haematology.

[14]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[15]  Timothy L Lash,et al.  The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients , 2011, BMC medical research methodology.

[16]  Y. Tomiyama,et al.  Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review , 2011, International journal of hematology.

[17]  H. Sørensen,et al.  Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: A Danish nationwide study , 2010, American journal of hematology.

[18]  Timothy L Lash,et al.  Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank , 2010, Clinical epidemiology.

[19]  S. Vesely,et al.  The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports , 2010, American journal of hematology/oncology.

[20]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[21]  B. Bain,et al.  Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. , 2009, Blood.

[22]  J. Logie,et al.  The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature review , 2009, European journal of haematology.

[23]  F. Mowat,et al.  Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database , 2009, British journal of haematology.

[24]  M. Nørgaard,et al.  Validity of a procedure to identify patients with chronic idiopathic thrombocytopenic purpura in the Danish National Registry of Patients , 2009, Clinical epidemiology.

[25]  N. J. Robinson,et al.  Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal , 2008, Journal of thrombosis and haemostasis : JTH.

[26]  N. Powe,et al.  Prevalence of immune thrombocytopenia: analyses of administrative data , 2006, Journal of thrombosis and haemostasis : JTH.

[27]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[28]  S. Proctor,et al.  Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients , 2003, British journal of haematology.

[29]  V. Blanchette,et al.  Immune thrombocytopenic purpura. , 2002, The New England journal of medicine.

[30]  T. Tony Cai,et al.  Confidence Intervals for a binomial proportion and asymptotic expansions , 2002 .

[31]  K. Schmidt,et al.  The incidence of idiopathic thrombocytopenic purpura in adults increases with age. , 1999, Blood.